These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 27616574

  • 21. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW, Chen TC, Huang HS, Lee H.
    Cell Death Dis; 2016 Jun 30; 7(6):e2290. PubMed ID: 27362807
    [Abstract] [Full Text] [Related]

  • 22. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 30; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 23. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
    Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P, Huang L.
    Sci Rep; 2015 Jul 13; 5():8477. PubMed ID: 26166037
    [Abstract] [Full Text] [Related]

  • 24. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J, Kim SH.
    Cell Physiol Biochem; 2014 Jul 13; 34(3):865-72. PubMed ID: 25199820
    [Abstract] [Full Text] [Related]

  • 25. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 13; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

  • 26. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
    Park SE, Kim DE, Kim MJ, Lee JS, Rho JK, Jeong SY, Choi EK, Kim CS, Hwang JJ.
    Oncol Rep; 2019 Jan 13; 41(1):525-533. PubMed ID: 30365122
    [Abstract] [Full Text] [Related]

  • 27. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.
    Cancer Chemother Pharmacol; 2010 Jul 13; 66(2):381-8. PubMed ID: 19921194
    [Abstract] [Full Text] [Related]

  • 28. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.
    Anticancer Res; 2019 Apr 13; 39(4):1767-1775. PubMed ID: 30952716
    [Abstract] [Full Text] [Related]

  • 29. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C, Gao W, Liu J, Cheng H, Hao J.
    Respir Res; 2020 Aug 10; 21(1):210. PubMed ID: 32778129
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.
    Cancer Res; 2008 Jan 15; 68(2):589-96. PubMed ID: 18199556
    [Abstract] [Full Text] [Related]

  • 31. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS, Yang H, Choi J, Seo S, Kim D, Lee CH, Jeon H, Kim SW, Lee DH.
    Cancer Lett; 2017 Oct 10; 406():47-53. PubMed ID: 28797845
    [Abstract] [Full Text] [Related]

  • 32. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
    Wang H, Fei Z, Jiang H.
    J Pharmacol Sci; 2017 Jul 10; 134(3):190-196. PubMed ID: 28757172
    [Abstract] [Full Text] [Related]

  • 33. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN, Lee MH, Kim E, Yoon G, Chae JI, Shim JH.
    Phytomedicine; 2019 Oct 10; 63():153014. PubMed ID: 31323446
    [Abstract] [Full Text] [Related]

  • 34. Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
    Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L, Leung EL.
    Molecules; 2014 Mar 21; 19(3):3508-22. PubMed ID: 24662070
    [Abstract] [Full Text] [Related]

  • 35. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW, Lee DH.
    Cancer Lett; 2016 Mar 01; 372(1):75-81. PubMed ID: 26723875
    [Abstract] [Full Text] [Related]

  • 36. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 01; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 37. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K, Wang L, Wei A, Jia X, Liu X.
    Thorac Cancer; 2020 Jun 01; 11(6):1566-1577. PubMed ID: 32368855
    [Abstract] [Full Text] [Related]

  • 38. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 01; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 39. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.
    Hidayat M, Mitsuishi Y, Takahashi F, Tajima K, Yae T, Miyahara K, Hayakawa D, Winardi W, Ihara H, Koinuma Y, Wirawan A, Nurwidya F, Kato M, Kobayashi I, Sasaki S, Takamochi K, Hayashi T, Suehara Y, Moriyama M, Moriyama H, Habu S, Takahashi K.
    Bosn J Basic Med Sci; 2019 Nov 08; 19(4):355-367. PubMed ID: 31202256
    [Abstract] [Full Text] [Related]

  • 40. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J, Kwak KJ, Wu Z, Yang D, Li J, Chang M, Song Y, Zeng H, Lee LJ, Hu J, Bai C.
    Cell Physiol Biochem; 2018 Nov 08; 47(5):1909-1924. PubMed ID: 29961070
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.